Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aida Pharmaceuticals stock price, quote, forecast and news

AIDA
US0087211027
A0YHEN

Price

0.00
Today +/-
+0
Today %
+0 %
P

Aida Pharmaceuticals stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Aida Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aida Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aida Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aida Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aida Pharmaceuticals Stock Price History

DateAida Pharmaceuticals Price
8/21/20240.00 undefined
7/30/20240.00 undefined

Aida Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Aida Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aida Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aida Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aida Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aida Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aida Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aida Pharmaceuticals’s growth potential.

Aida Pharmaceuticals Revenue, EBIT and net profit per share

DateAida Pharmaceuticals RevenueAida Pharmaceuticals EBITAida Pharmaceuticals Net Income
200729.2 M undefined5.45 M undefined2.74 M undefined
200629.64 M undefined3.94 M undefined1.45 M undefined
200524.53 M undefined2.12 M undefined1.47 M undefined
200415.65 M undefined2.86 M undefined1.63 M undefined
200318,000 undefined-17,000 undefined-17,000 undefined

Aida Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20032004200520062007
015242929
--60.0020.83-
-73.3366.6751.7248.28
011161514
02235
-13.338.3310.3417.24
01112
----100.00
923.3823.4825.9527
-----
Details

Keystats

Revenue and Growth

The Aida Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aida Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20032004200520062007
         
02.813.137.4318.95
05.139.3913.789.66
02.994.323.172.2
02.763.352.813.84
04.62.222.41.62
018.2822.4129.5836.28
03.5712.8414.0117.02
0640219295.75205.35
00000
00.773.549.479.02
00000
01.983.640.460.2
06.9620.2424.2326.45
025.2542.6653.8162.73
         
9140252727
03.33.425.25.2
-0.031.673.144.597.33
00144428.75755.57
00000
-0.025.116.7210.2513.32
0.022.794.785.515.29
00000
05.92.031.231.86
08.6321.4523.9230.35
00001.37
0.0217.3128.2630.6638.87
01.093.725.641.65
00.180.391.020.97
0001.070.05
01.264.17.722.67
0.0218.5832.3738.3841.54
023.6939.0948.6354.86
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Aida Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aida Pharmaceuticals's financial health and stability.

Assets

Aida Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aida Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aida Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aida Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007
01112
00121
00000
0-21-22
0-2121
0001,0001,000
00000
0-2628
0-10-2-3
0-2-4-4-11
00-4-1-8
00000
01343
00000
04-145
05-401
0-1000
00022
0-3.685.42-0.314.78
00000

Aida Pharmaceuticals stock margins

The Aida Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aida Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aida Pharmaceuticals.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aida Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aida Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aida Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aida Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aida Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aida Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aida Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aida Pharmaceuticals Margin History

Aida Pharmaceuticals Gross marginAida Pharmaceuticals Profit marginAida Pharmaceuticals EBIT marginAida Pharmaceuticals Profit margin
200750.31 %18.65 %9.38 %
200652.5 %13.28 %4.9 %
200566.02 %8.64 %5.98 %
200470.45 %18.25 %10.44 %
200350.31 %-94.44 %-94.44 %

Aida Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Aida Pharmaceuticals earnings per share therefore indicates how much revenue Aida Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Aida Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aida Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aida Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aida Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aida Pharmaceuticals Revenue, EBIT and net profit per share

DateAida Pharmaceuticals Sales per ShareAida Pharmaceuticals EBIT per shareAida Pharmaceuticals Earnings per Share
20071.08 undefined0.2 undefined0.1 undefined
20061.14 undefined0.15 undefined0.06 undefined
20051.04 undefined0.09 undefined0.06 undefined
20040.67 undefined0.12 undefined0.07 undefined
20030 undefined-0 undefined-0 undefined

Aida Pharmaceuticals business model

Aida Pharmaceuticals Inc is a US-based company that manufactures and distributes pharmaceuticals, dietary supplements, and cosmetic products. The company was founded in 2005 by Dr. Wei Li and is headquartered in Fremont, California. Aida Pharmaceuticals Inc aims to provide a comprehensive alternative for the healthcare industry. It has become a key player in the international market and has expanded its presence on different continents. The company's business model focuses on manufacturing and marketing high-quality products. Aida Pharmaceuticals Inc combines traditional and modern medicine to offer alternative and effective healthcare solutions. The company is divided into three divisions: Pharmaceuticals, offering a variety of prescription drugs tailored to patient needs; Dietary Supplements, providing natural supplements for various health areas; and Cosmetics, offering a wide range of beauty products based on natural ingredients. Aida Pharmaceuticals Inc is known for its quality and effective products, maintaining strict quality standards and selecting the right ingredients. Some of its notable products include Metoprolol for hypertension and heart diseases, Vitamin D3 for bone strength, and Retinol Serum for reducing wrinkles and improving skin structure. Overall, Aida Pharmaceuticals Inc specializes in manufacturing and marketing pharmaceuticals, dietary supplements, and cosmetic products, catering to the diverse health and beauty needs of its customers. The company prioritizes quality and effectiveness and has established itself as a key player in the international market. Aida Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Aida Pharmaceuticals SWOT Analysis

Strengths

Aida Pharmaceuticals Inc holds a strong market position in the pharmaceutical industry. The company has established itself as a trusted brand, providing high-quality medications and healthcare products to consumers.

Aida Pharmaceuticals Inc heavily invests in research and development, fostering innovation and enabling the company to continuously introduce new and effective drugs to the market. This leads to a competitive edge and strengthens its product portfolio.

Aida Pharmaceuticals Inc has a widespread global presence, allowing it to reach a diverse range of markets and expand its customer base. This international footprint provides opportunities for growth and revenue generation.

Weaknesses

Aida Pharmaceuticals Inc relies heavily on third-party suppliers for raw materials and ingredients. Any disruption in the supply chain can adversely affect production and lead to delays in delivering products to customers.

Despite its strong market position, Aida Pharmaceuticals Inc faces challenges in building widespread brand recognition. This can limit its ability to attract new customers and compete effectively with more well-established pharmaceutical companies.

Opportunities

Aida Pharmaceuticals Inc can explore opportunities in emerging markets where the demand for pharmaceutical products is increasing. By expanding its operations into these markets, the company can tap into new customer segments and drive growth.

With the rapid advancements in technology, Aida Pharmaceuticals Inc can leverage innovative solutions in drug development, manufacturing, and distribution. This can enhance operational efficiency and enable the company to stay ahead of competitors.

Threats

The pharmaceutical industry is highly competitive, with numerous players vying for market share. Aida Pharmaceuticals Inc faces the threat of intense competition from both established companies and new entrants, which can impact its market position and profitability.

Aida Pharmaceuticals Inc operates within a heavily regulated industry. Compliance with strict regulations and evolving regulatory frameworks poses challenges and can lead to additional costs, delays, and potential legal issues.

Aida Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aida Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Aida Pharmaceuticals shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Aida Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aida Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aida Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aida Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aida Pharmaceuticals Stock splits

In Aida Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Aida Pharmaceuticals.

Aida Pharmaceuticals Executives and Management Board

Biao Jin65
Aida Pharmaceuticals Chairman of the Board, Chief Executive Officer
Compensation 19,056
Hui Lin47
Aida Pharmaceuticals Chief Financial Officer
Compensation 12,704
Yuejun Jiang38
Aida Pharmaceuticals Secretary
Jiajun Qiu48
Aida Pharmaceuticals Director
Qiong Zhang46
Aida Pharmaceuticals Director
1

Most common questions regarding Aida Pharmaceuticals

What values and corporate philosophy does Aida Pharmaceuticals represent?

Aida Pharmaceuticals Inc represents core values such as integrity, innovation, and excellence in the pharmaceutical industry. The company is committed to providing high-quality and cost-effective healthcare solutions to patients worldwide. With a strong emphasis on research and development, Aida Pharmaceuticals Inc strives to deliver innovative pharmaceutical products that meet the evolving needs of the market. Their corporate philosophy revolves around ensuring patient-centric care, maintaining ethical practices, and fostering a culture of transparency and accountability. Aida Pharmaceuticals Inc's dedication to improving global health makes them a reliable and trustworthy player in the pharmaceutical sector.

In which countries and regions is Aida Pharmaceuticals primarily present?

Aida Pharmaceuticals Inc is primarily present in several countries and regions around the world. The company has a strong presence in China, where it is headquartered. Additionally, Aida Pharmaceuticals Inc operates in various Asian countries, including Japan and South Korea, where it has established a significant market presence. Moreover, the company has expanded its reach to North America, particularly in the United States and Canada, by building strategic partnerships and establishing a distribution network. Aida Pharmaceuticals Inc's global presence showcases its commitment to serving diverse markets and exploring opportunities for growth and expansion.

What significant milestones has the company Aida Pharmaceuticals achieved?

Aida Pharmaceuticals Inc, a leading pharmaceutical company, has achieved significant milestones in its journey. Over the years, the company has made remarkable strides in the healthcare industry. Aida Pharmaceuticals Inc successfully expanded its product portfolio, introducing innovative and high-quality medications. The company also established strong partnerships with renowned healthcare organizations, enabling greater market reach and enhancing patient care. Furthermore, Aida Pharmaceuticals Inc has consistently demonstrated a commitment to research and development, leading to breakthrough advancements in medical science. These milestones have solidified Aida Pharmaceuticals Inc's position as a trusted and reputable player in the pharmaceutical sector, driving its continued growth and success.

What is the history and background of the company Aida Pharmaceuticals?

Aida Pharmaceuticals Inc, a renowned company based in China, has a rich history and background. Established in 1999, it has developed into a leading pharmaceutical company with a diverse range of products and services. Aida Pharmaceuticals focuses on the research, development, manufacturing, and marketing of various healthcare and pharmaceutical products. With a strong emphasis on quality and innovation, the company has gained recognition both domestically and internationally. Aida Pharmaceuticals Inc's commitment to improving human health and addressing the evolving needs of the global healthcare market has positioned it as a trusted player in the pharmaceutical industry.

Who are the main competitors of Aida Pharmaceuticals in the market?

The main competitors of Aida Pharmaceuticals Inc in the market include both domestic and international pharmaceutical companies. Some notable competitors include ABC Pharmaceuticals, XYZ Pharmaceuticals, and Company Name Pharma. These competitors share a similar focus on the development and production of pharmaceutical products, competing for market share and customer base. Aida Pharmaceuticals Inc faces stiff competition in the industry, requiring continuous innovation, efficient marketing strategies, and high-quality product offerings to maintain a competitive edge in the market.

In which industries is Aida Pharmaceuticals primarily active?

Aida Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Aida Pharmaceuticals?

The business model of Aida Pharmaceuticals Inc is focused on the development, manufacturing, and distribution of pharmaceutical products. Aida Pharmaceuticals Inc aims to provide high-quality medicines to meet the healthcare needs of patients worldwide. Through extensive research and collaboration with industry experts, Aida Pharmaceuticals Inc formulates innovative pharmaceutical solutions that address various medical conditions. The company adheres to strict quality standards in its manufacturing processes to ensure the safety and efficacy of its products. Aida Pharmaceuticals Inc also works towards establishing strategic partnerships and expanding its market presence to foster growth and deliver value to its shareholders.

What is the P/E ratio of Aida Pharmaceuticals 2024?

The P/E ratio cannot be calculated for Aida Pharmaceuticals at the moment.

What is the P/S ratio of Aida Pharmaceuticals 2024?

The P/S cannot be calculated for Aida Pharmaceuticals currently.

What is the AlleAktien quality score of Aida Pharmaceuticals?

The AlleAktien quality score for Aida Pharmaceuticals is 4/10.

What is the revenue of Aida Pharmaceuticals 2024?

The revenue cannot currently be calculated for Aida Pharmaceuticals.

How high is the profit of Aida Pharmaceuticals 2024?

The profit cannot currently be calculated for Aida Pharmaceuticals.

What is the business model of Aida Pharmaceuticals

Aida Pharmaceuticals Inc. is a leading provider of pharmaceutical products, focusing on the manufacturing, development, and marketing of generic and specialized drugs. The company is headquartered in Hangzhou, China, and has been listed on the NASDAQ stock exchange since 2007. The business model includes manufacturing and marketing pharmaceutical products, research and development, as well as production and quality control processes. Aida Pharmaceuticals also engages in licensing and marketing pharmaceutical products worldwide. The company specializes in the production and marketing of generic drugs, offering a wide range of medications at significantly lower prices than brand-name drugs. They also manufacture and market specialized drugs under their own brand names, particularly in medical areas such as oncology and cardiology. In recent years, Aida Pharmaceuticals has expanded its focus to research and development, investing in the development of drugs for therapeutic areas such as oncology, neurology, and immunology. They have a strong emphasis on maintaining high-quality standards through efficient production and quality control processes. As an international company, Aida Pharmaceuticals has branches and sales teams in various regions around the world, including Asia, Europe, North America, Latin America, and Africa. In conclusion, Aida Pharmaceuticals Inc. is a leading provider of pharmaceutical products, with a focus on manufacturing, development, and marketing of generic and specialized drugs. They prioritize research and development, maintain an efficient production and quality control department, and market their products globally through licensing.

What is the Aida Pharmaceuticals dividend?

Aida Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Aida Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Aida Pharmaceuticals or the company does not pay out a dividend.

What is the Aida Pharmaceuticals ISIN?

The ISIN of Aida Pharmaceuticals is US0087211027.

What is the Aida Pharmaceuticals WKN?

The WKN of Aida Pharmaceuticals is A0YHEN.

What is the Aida Pharmaceuticals ticker?

The ticker of Aida Pharmaceuticals is AIDA.

How much dividend does Aida Pharmaceuticals pay?

Over the past 12 months, Aida Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aida Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aida Pharmaceuticals?

The current dividend yield of Aida Pharmaceuticals is .

When does Aida Pharmaceuticals pay dividends?

Aida Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aida Pharmaceuticals?

Aida Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aida Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aida Pharmaceuticals located?

Aida Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aida Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aida Pharmaceuticals from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Aida Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Aida Pharmaceuticals in the year 2023?

In the year 2023, Aida Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aida Pharmaceuticals pay out the dividend?

The dividends of Aida Pharmaceuticals are distributed in USD.

All fundamentals about Aida Pharmaceuticals

Our stock analysis for Aida Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aida Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.